CSL.AX Stock Today April 04: Pivot, Guidance Intact as Sales Rebound

The CSL share price is back in focus for ASX investors after management reaffirmed full‑year guidance and flagged an early sales recovery in the United States and China. That update has lifted hopes the stock may have found a floor. At the latest snapshot, CSL.AX traded near A$138.93, well below its 50‑day and 200‑day averages. We unpack what this pivot means, where key levels sit today, and how CSL Behring sales trends could shape the next leg for CSL stock ASX holders.

Guidance intact: what it means for investors

CSL’s CFO said the group is simplifying to speed decisions and reaffirmed full‑year guidance, citing early sales recovery in the US and China. The strategy aims to cut complexity and refocus capital on higher‑return opportunities. This message, reported by the Australian Financial Review, supports the view that operational momentum is building and sentiment could stabilise the CSL share price. See coverage: AFR.

Investors have priced in a long slump after multi‑year lows, so confirmation that CSL earnings guidance is intact is meaningful. Early top‑line traction can lead margins higher as utilisation improves. With plasma volumes already normalised, incremental mix and pricing gains matter. If confidence in execution builds through FY26, the CSL share price could rerate toward historical ranges rather than sit near depressed multiples.

Today’s price setup and key technical levels

Price A$138.93, day range A$138.35–A$143.30, 52‑week range A$133.35–A$275.79. The CSL share price sits below the 50‑day average A$153.91 and 200‑day A$194.31. RSI is 39, near oversold territory. Bollinger lower band is A$136.03, with Keltner lower near A$134.98, marking a potential support zone. A sustained close above A$141–A$143 would signal an attempt to base.

MACD histogram has turned positive, while ADX at 27 suggests a strong trend still in place, though down‑bias lingers. ATR at 3.76 implies wider daily swings. For near‑term traders, support sits around A$135–A$136 and resistance at A$146–A$150. A move through the middle Bollinger band near A$141 could attract momentum buyers and help stabilise the CSL share price.

Valuation and cash flow check

At A$138.93, P/E is 15.4 based on the provided EPS of 9.01. Price to sales is about 3.0 and price to book is 2.5. Dividend yield sits near 3.1%. Operating margin is roughly 25.7% and free cash flow yield about 6.8%. Debt to equity near 0.67 looks manageable. These metrics frame risk and upside for the CSL share price.

Recent local analysis highlights practical ways to value CSL, noting the gap to longer‑run multiples as execution improves. The discussion points to upside if confidence in cash generation returns and guidance holds. For a concise walkthrough, see Rask Media. We think progress on margins could be the swing factor for CSL stock ASX investors.

CSL Behring sales recovery and 2026 watchlist

CSL Behring sales benefit from volume recovery, product mix and pricing discipline. As US and China demand rebuilds, fixed‑cost leverage can lift margins. Inventory and working capital efficiency also matter, with days of inventory at about 298 and current ratio near 2.57. If mix tilts toward higher‑margin immunology and specialty therapies, the CSL share price could respond to sustained EBIT growth.

Key milestones include the next trading update and FY26 results scheduled for 18 August 2026. Watch CSL earnings guidance, margin trajectory, Seqirus flu season performance, FX impact and capital allocation. Risks include pricing pressure, regulatory timelines and execution on simplification. A clean run on these items would strengthen the case for a medium‑term rerate in the CSL share price.

Final Thoughts

We see three pillars supporting interest in CSL today. First, management reaffirmed guidance and flagged early sales recovery in core markets. Second, technicals show the CSL share price near support, with clear levels to manage risk. Third, valuation is no longer stretched, and cash generation looks capable of rebuilding as utilisation and mix improve. From here, we would track updates on margins, capital discipline and CSL Behring sales, plus a move back above the mid‑bands near A$141–A$143. For longer‑term investors, the August result is the key checkpoint to validate momentum and keep the CSL share price in a constructive range.

FAQs

Is the CSL share price cheap now?

On basic metrics, CSL trades on about 15 times earnings, near 3 times sales and 2.5 times book, with a dividend yield around 3%. That is below many past cycles. If margins and sales rebuild, the multiple could expand. If recovery stalls, the current valuation may be fair.

What is the latest on CSL earnings guidance?

Management reaffirmed full‑year guidance and cited early recovery in US and China sales, according to local reporting. Investors will look for confirmation in the next update and the August 18 results. Any improvement in mix and margins would strengthen confidence in guidance delivery.

What technical levels matter for CSL stock ASX today?

We are watching support around A$135–A$136 and resistance at A$146–A$150. The middle Bollinger band near A$141 is a pivotal level. RSI near 39 implies the stock is close to oversold. A sustained close above A$143 would improve the near‑term setup.

What could lift CSL Behring sales further in 2026?

Improving demand in the US and China, favourable therapy mix, and disciplined pricing can help. Operational simplification may speed decisions and resource allocation. If inventory and utilisation improve, margins could follow. Stronger Seqirus seasonality and stable FX would also support group revenue and earnings.

Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.